# Clinical Trials Data ALK - Document 26

# An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy

## Clinical Trial: https://clinicaltrials.gov/study/NCT02069535

"eligibilityCriteria": "Inclusion Criteria:\n\n\* A documented clinically relevant history of Cupressus arizonica pollen induced allergic rhinoconjunctivitis with or without asthma for at least one year prior to trial entry.\n\* Positive Skin Prick Test (SPT) response to Cupressus arizonica pollen (wheal diameter \u2265 3 mm)\n\nExclusion Criteria:\n\n\* History of severe asthma exacerbation or emergency room visit or admission for asthma in the previous 12 months.\n\* Previous treatment with immunotherapy with Cupressus arizonica pollen extract within the last 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment has been discontinued before reaching maintenance dose; for SLIT 3 months in the last 5 years is accepted).\n\* Ongoing treatment with any allergen-specific immunotherapy product.\n\* A history of anaphylaxis with cardiorespiratory symptoms (immunotherapy, exercise-induced, food allergy, drugs or an idiopathic reaction).\n\* A systemic disease affecting the immune system (e.g. insulin-dependent diabetes, autoimmune disease, immune complex disease, or immune deficiency disease whether acquired or not).",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided inclusion and exclusion criteria for this clinical trial, the presence of an ALK gene mutation is not explicitly mentioned as a factor in determining eligibility. The criteria provided focus on allergic rhinoconjunctivitis related to Cupressus arizonica pollen, asthma history, prior immunotherapy, systemic diseases affecting the immune system, and specific allergen sensitivities.   
  
To determine eligibility based on an ALK gene mutation, you would need to check if the clinical trial has additional criteria regarding genetic mutations. However, from the criteria provided, an ALK gene mutation does not appear to directly affect eligibility for this study. If there are no additional criteria available, it would be safe to assume the mutation does not impact eligibility.   
  
It's always best for the patient to discuss their specific situation with the clinical trial coordinators for any underlying aspects that might affect participation, or to find out if more specific mutation-related criteria are applicable elsewhere in the trial documentation.